These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22209376)

  • 1. Novel molecular targets for the therapy of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sternberg CN
    Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
    Ouzaid I; Ravery V; Pouessel D; Culine S
    Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapies for metastatic castrate-resistant prostate cancer.
    Dayyani F; Gallick GE; Logothetis CJ; Corn PG
    J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New agents for prostate cancer.
    Agarwal N; Di Lorenzo G; Sonpavde G; Bellmunt J
    Ann Oncol; 2014 Sep; 25(9):1700-1709. PubMed ID: 24658665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Strategy in advanced castration-resistant prostate cancer].
    Gross-Goupil M; Roca S; Pasticier G; Ravaud A
    Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of metastatic castration-resistant prostate cancer following docetaxel].
    Beuzeboc P; Ropert S; Goldwasser F; Zerbib M
    Bull Cancer; 2012 Jul; 99 Suppl 1():S66-72. PubMed ID: 22516457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic castration-resistant prostate cancer: time for innovation.
    Tucci M; Scagliotti GV; Vignani F
    Future Oncol; 2015; 11(1):91-106. PubMed ID: 25572785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New hope in the treatment of advanced cancer of the prostate in 2012].
    Massard C
    Bull Cancer; 2012 Jul; 99 Suppl 1():S3. PubMed ID: 23767051
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel and bone-targeted agents for CRPC.
    Fizazi K; Albiges L; Massard C; Escudier B; Loriot Y
    Ann Oncol; 2012 Sep; 23 Suppl 10():x264-7. PubMed ID: 22987974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic fracture in patients with metastatic prostate cancer.
    Gartrell BA; Saad F
    Curr Opin Urol; 2014 Nov; 24(6):595-600. PubMed ID: 25166424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
    Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
    Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment options for patients with metastatic prostate cancer.
    Snoeks LL; Ogilvie AC; van Haarst EP; Siegert CE
    Neth J Med; 2013; 71(6):290-4. PubMed ID: 23956309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
    Galsky MD; Small AC; Tsao CK; Oh WK
    CA Cancer J Clin; 2012; 62(5):299-308. PubMed ID: 22535487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing landscape in metastatic castration-resistant prostate cancer.
    Leibowitz-Amit R; Joshua AM
    Curr Opin Support Palliat Care; 2013 Sep; 7(3):243-8. PubMed ID: 23817317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [How to manage patients with CRPC?].
    Beuzeboc P; Massard C
    Bull Cancer; 2015 Jun; 102(6):509-15. PubMed ID: 26028494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.